PMID- 34644425
OWN - NLM
STAT- MEDLINE
DCOM- 20211224
LR  - 20211224
IS  - 1098-2744 (Electronic)
IS  - 0899-1987 (Linking)
VI  - 61
IP  - 1
DP  - 2022 Jan
TI  - Low expression of lncRNA SBF2-AS1 regulates the miR-302b-3p/TGFBR2 axis, 
      promoting metastasis in laryngeal cancer.
PG  - 45-58
LID - 10.1002/mc.23358 [doi]
AB  - The 5-year survival rate of laryngeal cancer continues to decline, and the 
      laryngeal particularity of the anatomy adversely affects the patient's quality of 
      life. Emerging evidence suggests that long noncoding RNAs (lncRNAs) are closely 
      correlated to key steps in the malignant progression of cancer cells. In this 
      study, we report the role of lncRNA SBF2-AS1/miR-302b-3p/TGFBR2 interactions in 
      the metastasis of laryngeal squamous cell carcinoma (LSCC). We verified that 
      SBF2-AS1 was significantly downregulated in LSCC tissues and cell lines using 
      qRT-PCR analysis. Its low expression was correlated to lymph node metastasis and 
      an advanced clinical stage. More importantly, LSCC patients with low expression 
      of SBF2-AS1 tended to have a poor prognosis. Based on this, we performed 
      gain-of-function and loss-of-function experiments in LSCC cell lines. The results 
      confirmed that knocking down SBF2-AS1 can promote the metastasis of LSCC cells 
      and enhance epithelial-mesenchymal transition phenotype, while the upregulation 
      of SBF2-AS1 expression resulted in the opposite. Our in vivo model verified that 
      SBF2-AS1 overexpression could inhibit LSCC cell metastasis. Subsequent 
      mechanistic studies revealed that SBF2-AS1 acted as a competing endogenous RNA 
      that upregulated the expression of TGFBR2 by endogenous sponging for miR-302b-3p 
      in LSCC cell lines. Moreover, miR-302b-3p overexpression reversed the inhibitory 
      effects on LSCC metastasis induced by upregulation of SBF2-AS1 expression, and 
      inhibition of TGFBR2 expression reversed the effect of SBF2-AS1 on metastasis. 
      Our study proposes SBF2-AS1 as a biomarker to predict the prognosis of LSCC 
      patients and a novel potential therapeutic target.
CI  - (c) 2021 Wiley Periodicals LLC.
FAU - Li, Yun
AU  - Li Y
AD  - Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Tang, Bingjie
AU  - Tang B
AD  - Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Lyu, Kexing
AU  - Lyu K
AD  - Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Yue, Huijun
AU  - Yue H
AD  - Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Wei, Fanqin
AU  - Wei F
AD  - Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Xu, Yang
AU  - Xu Y
AD  - Department of Otolaryngology, Guangzhou First People's Hospital, School of 
      Medicine, South China University of Technology, Guangzhou, China.
FAU - Chen, Siyu
AU  - Chen S
AD  - Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Lin, Yu
AU  - Lin Y
AD  - Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Cai, Zhimou
AU  - Cai Z
AD  - Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Guo, Xueqin
AU  - Guo X
AD  - Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Li, Chunwei
AU  - Li C
AD  - Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Lei, Wenbin
AU  - Lei W
AUID- ORCID: 0000-0002-9720-1997
AD  - Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211013
PL  - United States
TA  - Mol Carcinog
JT  - Molecular carcinogenesis
JID - 8811105
RN  - 0 (MIRN302A microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (long non-coding RNA SBF2-AS1, human)
RN  - EC 2.7.11.30 (Receptor, Transforming Growth Factor-beta Type II)
RN  - EC 2.7.11.30 (TGFBR2 protein, human)
SB  - IM
MH  - Animals
MH  - Cell Line, Tumor
MH  - *Down-Regulation
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Laryngeal Neoplasms/genetics/*pathology
MH  - Male
MH  - Mice
MH  - MicroRNAs/*genetics
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Neoplasm Transplantation
MH  - RNA, Long Noncoding/*genetics
MH  - Receptor, Transforming Growth Factor-beta Type II/*genetics
OTO - NOTNLM
OT  - ceRNA
OT  - epithelial-mesenchymal transition
OT  - laryngeal cancer
OT  - lncRNA
OT  - metastasis
EDAT- 2021/10/14 06:00
MHDA- 2021/12/25 06:00
CRDT- 2021/10/13 17:31
PHST- 2021/09/03 00:00 [revised]
PHST- 2021/07/11 00:00 [received]
PHST- 2021/09/18 00:00 [accepted]
PHST- 2021/10/14 06:00 [pubmed]
PHST- 2021/12/25 06:00 [medline]
PHST- 2021/10/13 17:31 [entrez]
AID - 10.1002/mc.23358 [doi]
PST - ppublish
SO  - Mol Carcinog. 2022 Jan;61(1):45-58. doi: 10.1002/mc.23358. Epub 2021 Oct 13.